Background Prophylaxis for venous thromboembolism is recommended for at least 10 days
after total knee arthroplasty; oral regimens could enable shorter hospital stays. We aimed to …

Background: There is a clinical need for novel oral anticoagulants with predictable
pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in …

Purpose The non–vitamin K antagonist oral anticoagulants (NOACs), dabigatran, rivaroxaban,
and apixaban, provide several advantages over vitamin K antagonists, such as warfarin. …

Betrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of
venous thromboembolism (VTE). Its antithrombotic effects had not been previously tested in …

This article will show conclusively that "kinematic instability" is not inherent to the hybrid
position/force control scheme of robot manipulators but is a result of an incomplete and inap …

Postoperative deep vein thrombosis (DVT) occurs most often in the large veins of the legs in
patients undergoing major joint arthroplasty and major surgical procedures. These patients …

Cartilage-pannus junctions of the rheumatoid lesion have been examined by histochemical
and ultrastructural techniques in an attempt to identify the cells responsible for cartilage …

Background Aggrecan degradation is the hallmark of cartilage degeneration in osteoarthritis
(OA), though it is unclear whether a common proteolytic process occurs in all individuals. …

Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for
the prevention and treatment of venous thromboembolism (VTE). This analysis of pooled …

We have isolated a mutant of Escherichia cell K12 with an unusual cell division lesion. This
mutant divides to produce normal sized cells and produces, in addition, small anucleate …